ArticleWorld journal of nephrology2023
Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis.
Article in World journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.International journal of molecular sciences · 2026Article
- Integrated Bioinformatic Analysis of the Shared Molecular Mechanisms Between Diabetic Nephropathy and Atherosclerosis.Journal of inflammation research · 2026Article
- Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.Drug design, development and therapy · 2026Article
- Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.World journal of nephrology · 2025Review
- Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia.Scientific reports · 2025Article
- Pre-existing cardiovascular disease and hyperlipidemia and mortality in peritoneal dialysis patients.Frontiers in endocrinology · 2025Observational
- Altered albumin/neutrophil to lymphocyte ratio are associated with all-cause and cardiovascular mortality for advanced cardiovascular-kidney-metabolic syndrome.Frontiers in nutrition · 2025Article
- Correlation of the triglyceride-glucose-body mass index with all-cause and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study.Frontiers in nutrition · 2025Article
- The prognostic nutritional index as a predictor of cardiovascular and all-cause mortality in chronic kidney disease: a population-based analysis of NHANES data (1999-2018).Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliflozins or Sodium glucose cotransporter 2 inhibitors (SGLT2i) are relatively novel antidiabetic medications that have recently been shown to represent favorable effects on patients' cardiorenal outcomes. However, there is shortage of data on potential disparities in this therapeutic effect across different patient subpopulations.
aimTo investigate differential effects of SGLT2i on the cardiorenal outcomes of heart failure patients across left ventricular ejection fraction (LVEF) levels.
methodsLiterature was searched systematically for the large randomized double-blind controlled trials with long enough follow up periods reporting cardiovascular and renal outcomes in their patients regarding heart failure status and LVEF levels. Data were then meta-analyzed after stratification of the pooled data across the LVEF strata and New York Heart Associations (NYHA) classifications for heart failure using Stata software version 17.0.
resultsThe literature search returned 13 Large clinical trials and 13
conclusionHeart failure patients with lower LVEF and lower NYHA sub-classifications were found to be generally more likely to benefit from therapy with gliflozins. Further research are required to identify patient subgroups representing the highest benefits or adverse events in response to SGLT2i.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.